Search Result

Results for "

Efferocytosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Amylases (1) Amyloid-β (1) Apoptosis (2) Bacterial (1) COX (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) Epoxide Hydrolase (1) ERK (1) FAAH (1) Furin (1) Interleukin Related (1) JAK (1) MMP (1) NF-κB (1) NOD-like Receptor (NLR) (1) Notch (1) p38 MAPK (1) PAI-1 (1) PD-1/PD-L1 (1) Phospholipase (1) PI3K (1) Pregnane X Receptor (PXR) (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (1) Ser/Thr Protease (1) STAT (1) TAM Receptor (1) Tim3 (1) TNF Receptor (1) TREM receptor (1) Wnt (1) β-glucuronidase (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (5) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Akt (2)

Amylases (1)

Amyloid-β (1)

Apoptosis (2)

Bacterial (1)

COX (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (1)

Epoxide Hydrolase (1)

ERK (1)

FAAH (1)

Furin (1)

Interleukin Related (1)

JAK (1)

MMP (1)

NF-κB (1)

NOD-like Receptor (NLR) (1)

Notch (1)

p38 MAPK (1)

PAI-1 (1)

PD-1/PD-L1 (1)

Phospholipase (1)

PI3K (1)

Pregnane X Receptor (PXR) (1)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (1)

Ser/Thr Protease (1)

STAT (1)

TAM Receptor (1)

Tim3 (1)

TNF Receptor (1)

TREM receptor (1)

Wnt (1)

β-glucuronidase (1)

By Research Areas:

Cancer (6)

Cardiovascular Disease (5)

Inflammation/Immunology (7)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .

HY-34350

2-(Aminomethyl)phenol 2-Hydroxybenzylamine; o-Hydroxybenzylamine; 2-HOBA	Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology
2-(Aminomethyl)phenol (2-Hydroxybenzylamine) is a selective dicarbonyl scavenger. 2-(Aminomethyl)phenol is an antioxidant and scavanger of free radicals and isolevuglandins (IsoLGs). 2-(Aminomethyl)phenol can prevent early recurrence of atrial fibrillation. 2-(Aminomethyl)phenol can reduce inflammation and plaque apoptotic cells and promote efferocytosis and features of stable plaques. 2-(Aminomethyl)phenol can reduce malondialdehyde (MDA)-LDL and MDA-HDL levels in Ldlr ^-/- mouse model. 2-(Aminomethyl)phenol can be studied in the research of inflammation and cardiovascular disease, such as atherosclerosis, early recurrence of atrial fibrillation (AF) and arrhythmias .

HY-117548

UNC1062 2 Publications Verification	TAM Receptor Apoptosis p38 MAPK ERK PI3K Akt JAK STAT	Cardiovascular Disease Cancer
UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC₅₀ of 1.1 nM (Morrison K_i = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC₅₀ = 60 nM, AXL IC₅₀ = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage *efferocytosis*, and it suitable for research on atherosclerosis .

HY-155773

VU534	FAAH Epoxide Hydrolase	Cardiovascular Disease
VU534 is a NAPE-PLD activator, with an EC₅₀ of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC₅₀ of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study ^[1].

HY-155774

VU533 1 Publications Verification	Phospholipase	Metabolic Disease
APE-PLD (VU533) activator is a potent NAPE-PLD activator with an EC₅₀ value of 0.30 µM. NAPE-PLD activator (VU533) can enhance NAPE-PLD activity and increase efferocytosis by macrophages. NAPE-PLD activator (VU533) can be used for cardiometabolic diseases research .

HY-113533

Resolvin D4 RvD4	Bacterial	Inflammation/Immunology
Resolvin D4 (RvD4), a specialized proresolving mediator, can be produced in bioactive levels during S. aureus infection .

HY-N9454

Garcinoic acid	Pregnane X Receptor (PXR) COX NF-κB Amylases β-glucuronidase DNA/RNA Synthesis Amyloid-β NOD-like Receptor (NLR) Pyroptosis	Cancer
Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine α-amylase, Saccharomyces cerevisiae α-glucosidase and human DNA polymerase β (IC₅₀=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia .

HY-131993

Resolvin E4 RvE4	Endogenous Metabolite	Inflammation/Immunology
Resolvin E4 (RvE4) is an endogenous metabolite that stimulates efferocytosis of apoptotic neutrophils and senescent erythrocytes. Resolvin E4 enhances resolution of hemorrhagic exudates and inflammation in vivo .

HY-164502

NAP1051	Akt	Cancer
NAP1051 is a biomimetic analog of lipin A4 that achieves anti-tumor effects by targeting the inflammatory tumor microenvironment. NAP1051 inhibits neutrophil chemotaxis to fMLP and stimulates macrophage efferocytosis by activating AKT. NAP1051 can be used in colorectal cancer research .

HY-E70390

C1s Enzyme masp-2, c1 esterase, c1-esterase	Wnt	Cardiovascular Disease Inflammation/Immunology
C1s Enzyme is a subunit of the complement C1 complex, which activates the complement as a serine protease. C1s Enzyme cleaves LRP5 and LRP6, and thus activates the Wnt/β-Catenin signaling pathway. C1s Enzyme promotes the macrophage M2 polarization and inhibits M1 polarization. C1s Enzyme enhances efferocytosis, exhibits anti-inflammatory activity .

HY-P990716

Sabestomig AZD7789	PD-1/PD-L1 Tim3	Inflammation/Immunology
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .

HY-180109

Benzo-17R-RvD2 Benzo-17R-Resolvin D2	TNF Receptor Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Benzo-17R-RvD2 (Benzo-17R-Resolvin D2) is a benzo-containing analog of RvD2 (HY-121636). Benzo-17R-RvD2 enhances human macrophage efferocytosis, limits neutrophil infiltration, reduces TNF-α, and increases IL-1 receptor antagonist in peritonitis. Benzo-17R-RvD2 promotes E. coli killing by human leukocytes and reduces neutrophil swarm area without compromising anti-Candida activity. Benzo-17R-RvD2 activates the human-RvD2 receptor with an EC₅₀ ∼1.5 nM. Benzo-17R-RvD2 can be used in research on inflammation-associated diseases such as cardiovascular disease, cancer, neuroinflammation, pain, and muscle regeneration .

HY-183626

TM5614 sodium	PAI-1 Ser/Thr Protease Furin MMP Notch Apoptosis	Inflammation/Immunology Cancer
TM5614 sodium is an orally active and specific PAI-1 inhibitor with an IC₅₀ of <6.95 μM. TM5614 sodium blocks the interaction between PAI-1 and serine proteases or LRP-1, and enhances plasmin generation. TM5614 sodium restores macrophage efferocytosis and promotes macrophage polarization. TM5614 sodium alleviates PAI-1-mediated inhibition of Furin, promotes MT1-MMP maturation, activates the NOTCH1 signaling pathway, inhibits proliferation and induces apoptosis. TM5614 sodium promotes skeletal muscle regeneration and alleviates inflammation in a mouse model of skeletal muscle injury. TM5614 sodium can be used in research on skeletal muscle injury-induced inflammation and chronic myeloid leukemia .

Cat. No.	Product Name	Target	Research Area	Image